Jacobs Levy Equity Management, Inc Theravance Biopharma, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 576,447 shares of TBPH stock, worth $5.68 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
576,447
Previous 586,614
1.73%
Holding current value
$5.68 Million
Previous $4.97 Million
6.59%
% of portfolio
0.02%
Previous 0.02%
Shares
28 transactions
Others Institutions Holding TBPH
# of Institutions
122Shares Held
47.3MCall Options Held
200Put Options Held
12.8K-
Madison Avenue Partners, LP New York, NY9.51MShares$93.8 Million9.44% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$73.5 Million1.94% of portfolio
-
Newtyn Management, LLC New York, NY4.5MShares$44.4 Million6.4% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$37.3 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$27.2 Million1.95% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $658M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...